Formulation

Model informed formulation development uses in-silico modeling and simulation to identify and/or refine promising formulations faster and cheaper, support formulation strategy and increasingly, demonstrate virtual bioequivalence and obtain biowaivers.

A new generation of interactive formulation development platforms can leave trial and error in the formulation process in the past.

The Start-Up Market at CPHI Barcelona will bring together 27 start-ups, innovators, and small enterprises from across the pharma landscape.

When considering manufacturing and the growth of drug formulation, it is evident that there has been change and many new advancements introduced to make processes more efficient.

Sherma Ellis Daal, brand director, Pharma at Informa Markets, gives a preview of CPHI Barcelona 2023.

CPHI’s Annual Report predicts huge impact of AI on drug development and manufacturing.

Dosage forms are being shaped by numerous factors, with patient-centricity continuing to be an important driver of decisions in development.

In this episode of Drug Digest, Pharmaceutical Technology’s European/Senior Editor, Felicity Thomas, discusses small-molecule APIs, excipients, and formulation advances, including a discussion about novel approaches and solutions to pediatric formulations and taste-masking, a rundown of the fundamental stages of gaining a certificate of suitability for APIs, and a deliberation on the biggest trends impacting the industry and key sessions to visit while at CPHI, with several key industry experts.

Excipients should be treated equally when it comes to quality management, risk assessment, and testing.

Coprocessed excipients save time and cost while improving performance in a widening array of dosage forms.

The biggest hurdle is developing palatable formulations that are efficacious and patient friendly.

Sample dilution, sensitivity, excipient interference, and containment are key issues that must be addressed.

Nanotech-based delivery technologies are receiving significant attention.

This deal would help the companies merge to work on future projects and conduct research together.

Vibha Jawa, executive director at Bristol Myers Squibb, discusses foreign epitopes recognition from what should be fully human antibody therapies.

Process control is essential for using continuous hot-melt extrusion to enhance solubility.

Unique solutions are required to protect inherently unstable messenger RNA.

Despite the advantages intensified processes can offer developers, there are still some obstacles to overcome before broader application of new technologies will be implemented.

Polyplus’ LipidBrick is designed to expand the scope of lipid nanoparticle formulation usage in mRNA therapeutics and vaccine development.

Under a technology licensing agreement with Bhami Research Laboratory, Catalent intends to develop formulations that will allow for the delivery of high-concentration biologics subcutaneously.

Webinar Date/Time: Session 1: Tuesday, February 28th , 2023 at 4pm GMT | 11am EDT | 5pm CEST Session 2: Wednesday, March 22nd, 2023 4:00pm GMT | 11:00 am EDT | 5:00 pm CEST Session 3: Thursday, April 20th, 2023 at 4 GMT | 11am EDT | 5pm CEST

Webinar Date/Time: Thu, Mar 30, 2023 11:00 AM EDT

This article discusses the evaluation of paired content uniformity and weight variation data sets using F and T tests to ensure that batches meet compendial requirements.

Advancements in therapeutic modalities are necessitating change in drug delivery to help negate some of the expense of development and manufacturing.

Inhaled vaccines must resist degradation and penetrate the mucosal lining in the airways and lungs.

Advancements in soft capsule technology can enable the development of soft capsule formulations, which are becoming the preferred method of oral administration.

High-concentration injectable formulations present unique challenges.

Opportunities and developments in particle engineering are providing developers with the tools to advance drug candidates successfully.

Gerresheimer has developed a new dropper insert for ophthalmic formulations that it is showcasing at CPHI 2022 in Frankfurt, Germany.

Aenova Group and Microcaps are partnering to enable new customized formulations for product development and life cycle management solutions.